This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Oxytocin nasal spray administered at 24 IU per day for five weeks significantly improved caregiver-rated social responsiveness in young children with autism compared to placebo. The treatment was well tolerated with mild side effects such as thirst, increased urination, and constipation.
Why it matters
This study provides early clinical evidence that oxytocin nasal spray may be a promising intervention to improve social deficits in young children with autism, a population with limited treatment options.
How the study worked
A double-blind, randomized, placebo-controlled, crossover clinical trial was conducted with 31 young children diagnosed with autism. Participants received oxytocin nasal spray and placebo each for five weeks, separated by a four-week washout period. Social responsiveness was assessed by caregiver ratings.
What this study cannot tell us
The study sample size was relatively small, and the evidence strength and long-term effects remain unclear. Further larger and longer-term studies are needed to confirm efficacy and safety.
Read the original research
The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial.
Molecular psychiatry, 21(9), 1225-31
Citation
Yatawara, C J; Einfeld, S L; Hickie, I B; Davenport, T A; Guastella, A J. (2016). The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial.. Molecular psychiatry, 21(9), 1225-31. https://doi.org/10.1038/mp.2015.162